News

Sleep Medicine Expert Daniel Gottlieb, MD, MPH, details a response to the USPSTF screening recommendations for obstructive sleep apnea in a primary care setting.

Phase 3 trial data from the INTEGUMENT-1 study yielded positive results for roflumilast cream on atopic dermatitis patients ages 6 and up.

Similar visual and anatomical outcomes were observed through 1 year, despite fewer injections in the mandated quarterly treated group.

US Prevention Services Task Force (USPSTF) announces that after reviewing the clinical utility of obstructive sleep apnea screening tools in a primary care setting, there's insufficient evidence to determine the balance between benefit and harm.

Anti-brolucizumab ADAs may be a risk factor for intraocular inflammation and retinal occlusive vasculitis in patients treated with brolucizumab.

Cognitive Behavioral Therapy (CBT) for insomnia is the front-line treatment for sleep disturbance. However, the effectiveness of this approach for those with primary brain tumors hasn't been evaluated until now.

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

New registry analysis shows persistent treatment with the IL-23 improved disease in patients predominately with a history of past biologic therapies.

"Having the ability to enhance the sleep quality in a way that is scientifically important, and also taking into account objective measurements opens a lot of possibilities," Gary Garcia-Molina, PhD, said in an interview.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

Approximately 20 million individuals in the US were living with AMD in 2019, including 18.34 million with early-stage AMD and 1.49 million with late-stage AMD.

Greater glaucoma polygenic risk was associated with faster structural and functional progression in early POAG, despite individuals receiving more intensive treatment.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

An expert rheumatologist provides an overview of the MIRROR trial and the reduction in tophus observed among patients with gout included in the trial.

In a recent study, patients with plaque psoriasis or vitiligo who were receiving phototherapy were found to have higher rates of skin cancer than the general population.

New research suggests that certain interleukin-17 blockage therapies may not alleviate sleeping issues in patients with psoriasis.

Intravitreal aflibercept, bevacizumab and ranibizumab were each associated with comparable significant decreases in RGCL thickness in nAMD.

Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.

A discussion with Dr. Lal regarding a recent 12-week trial evaluating the use of topical berdazimer gel for molluscum contagiosum.

The analysis additionally suggested the potential benefits of finerenone in the prevention of required ocular interventions.

David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.

A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.

Because unhealthy sleep is associated with multiple conditions and higher risk of mortality, investigators call for further research on the potential to optimize overall sleep health in the US.

New research suggests the use of simvastatin treatment may be helpful for patients with nonsegmental vitiligo and dyslipidemia.

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

Gary Garcia-Molina, PhD, explains precisely how Sleep Number smart bed technology works after conducting multiple sleep studies.

Aruna Pradhan, MD, MPH, joins The Heart Team at AHA 2022 to discuss the design, results, and her interpretation of the PROMINENT trial for practicing clinicians as well as how she interprets use of triglyceride-lowering agents in the wake of PROMINENT and RESPECT-EPA results.

The efficacy of H pylori treatments has waned in recent years, largely because of clarithromycin resistance.